Following the TRAIL to apoptosis

Bharti R. Chaudhari, Richard F. Murphy, Devendra K. Agrawal

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

Apoptosis, programmed cell death, eliminates injured or harmful cells. It can mediate its response through the actions of death ligands including TRAIL. TRAIL, a member of TNF superfamily, induces apoptosis of transformed cells through the action of death domain receptors DR-4 and DR5. It directly induces apoptosis through an extrinsic pathway, which involves the activation of caspases. TRAIL also is able to prevent apoptosis through the actions of its decoy receptors DcR-1 and DcR-2. Various regulators of TRAIL include FADD, IAPs, Bcl-2s, p53, and FLIPs. TRAIL is present in cells involved in asthma including eosinophils, mast cells, fibroblasts, and airway epithelial cells. It is expressed in airway remodeling and may be linked with the pathways of transforming growth factor-beta1, which is thought to cause damage to the epithelium. The repair process of the epithelium is hindered as a result of increased apoptosis induced by TGF-β1, which overlaps with the pathways of TRAIL. Analogs of TRAIL could have therapeutical applications for asthma. TRAIL is also seen as the basis for a "miracle" drug for cancer because of its ability to selectively kill cancer cells.

Original languageEnglish
Pages (from-to)249-262
Number of pages14
JournalImmunologic Research
Volume35
Issue number3
DOIs
StatePublished - Jul 2006

Fingerprint

Apoptosis
Asthma
Epithelium
Airway Remodeling
Transforming Growth Factor beta1
Death Domain Receptors
Caspases
Eosinophils
Mast Cells
Neoplasms
Cell Death
Fibroblasts
Epithelial Cells
Ligands
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Immunology

Cite this

Following the TRAIL to apoptosis. / Chaudhari, Bharti R.; Murphy, Richard F.; Agrawal, Devendra K.

In: Immunologic Research, Vol. 35, No. 3, 07.2006, p. 249-262.

Research output: Contribution to journalReview article

Chaudhari, Bharti R. ; Murphy, Richard F. ; Agrawal, Devendra K. / Following the TRAIL to apoptosis. In: Immunologic Research. 2006 ; Vol. 35, No. 3. pp. 249-262.
@article{4de346ff186b44df94a972aed1964412,
title = "Following the TRAIL to apoptosis",
abstract = "Apoptosis, programmed cell death, eliminates injured or harmful cells. It can mediate its response through the actions of death ligands including TRAIL. TRAIL, a member of TNF superfamily, induces apoptosis of transformed cells through the action of death domain receptors DR-4 and DR5. It directly induces apoptosis through an extrinsic pathway, which involves the activation of caspases. TRAIL also is able to prevent apoptosis through the actions of its decoy receptors DcR-1 and DcR-2. Various regulators of TRAIL include FADD, IAPs, Bcl-2s, p53, and FLIPs. TRAIL is present in cells involved in asthma including eosinophils, mast cells, fibroblasts, and airway epithelial cells. It is expressed in airway remodeling and may be linked with the pathways of transforming growth factor-beta1, which is thought to cause damage to the epithelium. The repair process of the epithelium is hindered as a result of increased apoptosis induced by TGF-β1, which overlaps with the pathways of TRAIL. Analogs of TRAIL could have therapeutical applications for asthma. TRAIL is also seen as the basis for a {"}miracle{"} drug for cancer because of its ability to selectively kill cancer cells.",
author = "Chaudhari, {Bharti R.} and Murphy, {Richard F.} and Agrawal, {Devendra K.}",
year = "2006",
month = "7",
doi = "10.1385/IR:35:3:249",
language = "English",
volume = "35",
pages = "249--262",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Following the TRAIL to apoptosis

AU - Chaudhari, Bharti R.

AU - Murphy, Richard F.

AU - Agrawal, Devendra K.

PY - 2006/7

Y1 - 2006/7

N2 - Apoptosis, programmed cell death, eliminates injured or harmful cells. It can mediate its response through the actions of death ligands including TRAIL. TRAIL, a member of TNF superfamily, induces apoptosis of transformed cells through the action of death domain receptors DR-4 and DR5. It directly induces apoptosis through an extrinsic pathway, which involves the activation of caspases. TRAIL also is able to prevent apoptosis through the actions of its decoy receptors DcR-1 and DcR-2. Various regulators of TRAIL include FADD, IAPs, Bcl-2s, p53, and FLIPs. TRAIL is present in cells involved in asthma including eosinophils, mast cells, fibroblasts, and airway epithelial cells. It is expressed in airway remodeling and may be linked with the pathways of transforming growth factor-beta1, which is thought to cause damage to the epithelium. The repair process of the epithelium is hindered as a result of increased apoptosis induced by TGF-β1, which overlaps with the pathways of TRAIL. Analogs of TRAIL could have therapeutical applications for asthma. TRAIL is also seen as the basis for a "miracle" drug for cancer because of its ability to selectively kill cancer cells.

AB - Apoptosis, programmed cell death, eliminates injured or harmful cells. It can mediate its response through the actions of death ligands including TRAIL. TRAIL, a member of TNF superfamily, induces apoptosis of transformed cells through the action of death domain receptors DR-4 and DR5. It directly induces apoptosis through an extrinsic pathway, which involves the activation of caspases. TRAIL also is able to prevent apoptosis through the actions of its decoy receptors DcR-1 and DcR-2. Various regulators of TRAIL include FADD, IAPs, Bcl-2s, p53, and FLIPs. TRAIL is present in cells involved in asthma including eosinophils, mast cells, fibroblasts, and airway epithelial cells. It is expressed in airway remodeling and may be linked with the pathways of transforming growth factor-beta1, which is thought to cause damage to the epithelium. The repair process of the epithelium is hindered as a result of increased apoptosis induced by TGF-β1, which overlaps with the pathways of TRAIL. Analogs of TRAIL could have therapeutical applications for asthma. TRAIL is also seen as the basis for a "miracle" drug for cancer because of its ability to selectively kill cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=33845872311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845872311&partnerID=8YFLogxK

U2 - 10.1385/IR:35:3:249

DO - 10.1385/IR:35:3:249

M3 - Review article

C2 - 17172650

AN - SCOPUS:33845872311

VL - 35

SP - 249

EP - 262

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 3

ER -